MediciNova Sees Unusually High Options Volume (NASDAQ:MNOV)

MediciNova, Inc. (NASDAQ:MNOV) was the target of some unusual options trading activity on Monday. Stock investors acquired 3,923 put options on the stock. This represents an increase of 2,235% compared to the average volume of 168 put options.

MediciNova Stock Performance

MNOV opened at $1.92 on Wednesday. The firm has a market cap of $94.50 million, a price-to-earnings ratio of -9.14 and a beta of 0.63. The firm’s 50-day simple moving average is $1.72 and its 200-day simple moving average is $1.50. MediciNova has a twelve month low of $1.17 and a twelve month high of $3.90.

MediciNova (NASDAQ:MNOV) last announced its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. The firm had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.07 million. MediciNova had a negative net margin of 1,168.70% and a negative return on equity of 26.51%. As a group, sell-side analysts anticipate that MediciNova will post -0.25 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder 3D Investment Partners Pte. Lt sold 640,000 shares of the company’s stock in a transaction dated Friday, September 25th. The shares were sold at an average price of $2.70, for a total value of $1,728,000.00. Following the sale, the insider owned 4,862,047 shares of the company’s stock, valued at $13,127,526.90. The trade was a 11.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 14.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in MediciNova stock. Bank of New York Mellon Corp acquired a new position in MediciNova, Inc. (NASDAQ:MNOV) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 78,277 shares of the biopharmaceutical company’s stock, valued at approximately $103,000. Bank of New York Mellon Corp owned approximately 0.16% of MediciNova as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 9.90% of the company’s stock.

MediciNova News Summary

Here are the key news stories impacting MediciNova this week:

• Positive Sentiment: H.C. Wainwright reiterated its Buy rating on MediciNova, signaling that the analyst sees value despite the clinical setback. H.C. Wainwright Reiterates Buy Rating on MediciNova
• Positive Sentiment: MN-001 produced statistically significant increases in HDL-C and HDL-P, an early triglyceride reduction, lower body weight, and a numerical improvement in liver fat. MediciNova Announces Topline Results from MN-001 Clinical Trial
• Negative Sentiment: The Phase 2 trial failed to meet its primary endpoints, prompting concerns about MN-001’s efficacy and contributing to the stock’s decline. MediciNova Shares Fall After Phase 2 Trial Miss
• Negative Sentiment: Unusually heavy put-option buying—3,923 contracts versus average volume of 168—reflects markedly increased bearish or hedging activity.
• Negative Sentiment: Major shareholder 3D Investment Partners sold 640,000 shares for approximately $1.73 million, reducing its position by 11.63%; the sale may add investor concern about near-term sentiment. SEC Ownership Filing

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Roth Capital began coverage on MediciNova in a report on Thursday, September 17th. They set a “buy” rating and a $6.00 price objective on the stock. HC Wainwright reissued a “buy” rating on shares of MediciNova in a report on Tuesday. Finally, Weiss Ratings upgraded MediciNova from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, September 2nd. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $7.75.

MediciNova Company Profile

MediciNova, Inc is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for neurological, inflammatory, and fibrotic diseases. The company does not currently market an approved product in the United States and instead advances candidates through clinical development and regulatory evaluation.

Its lead compound, MN-166 (ibudilast), is being investigated for conditions including progressive multiple sclerosis, amyotrophic lateral sclerosis, and substance-use disorders.